Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-19-001772.pdf
0001047469-19-001772.rtf
0001047469-19-001772.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-19-018709.pdf
0001104659-19-018709.rtf
0001104659-19-018709.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-19-017829.pdf
0001104659-19-017829.rtf
0001104659-19-017829.xls
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-19-001686.pdf
0001047469-19-001686.rtf
0001047469-19-001686.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-004061.pdf
0001179110-19-004061.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-004062.pdf
0001179110-19-004062.rtf
CT ORDER

CT ORDER

 View HTML
9999999997-19-001396.pdf
9999999997-19-001396.rtf
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-19-003920.pdf
0001179110-19-003920.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-001726.pdf
0001558370-19-001726.rtf
0001558370-19-001726.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-003446.pdf
0001179110-19-003446.rtf